Encouraging news for patients with Melanoma was disseminated on May 7, 2014 with the announcement that Vemurafenib and Cobimetinib look like the next powerful drug duo in the fight against this deadly cancer. Roche and Exelixis revealed that early stage trials of these formidable drugs have shown significant rates of extended survival, with plans underway for a Phase 3 study to commence.
Results from a Phase Ib trial, which involved 129 patients, demonstrated an overwhelming 87 percent overall response rate. The clinical trial participants who were administered with both Vemurafenib and Cobimetinib had not been treated with BRAF-blocking treatments prior to this trial. The median progression-free survival for the patients who received the Vemurafenib and Cobimetinib combination was 13.7 months. This figure was exemplary considering the prior rate of progression-free survival for patients dosed only with Vemurafenib was 2.8 months. While complete overall survival numbers are yet to be determined, leaders from the Phase Ib study predict that 83 percent of patients will experience at least a one year survival rate.
As a formidable cocktail geared for patients who have not exhibited previous BRAF-blocking history, the dynamic duo of Vemurafenib and Cobimetinib will continue to be evaluated in a pivotal Phase 3 trial. Coined coBRIM, this extensive trial is currently recruiting and evaluating patients and the initial data is already proving to be positive. Scientists have determined that combining the efficacious drug Cobimetinib with Vemurafenib offers a unique treatment option. The ability of Cobimetinib (also known as GDC-0973) to shut down the kinase MET, which acts as a growth factor regulator, helps to contain and keep tumors from proliferating. Vemurafenib is also a kinase inhibitor which successfully blocks abnormal protein which spurs cancer cells to multiply. Phase 1 and 2 clinical trials of Vemurafenib alone have proven to be viable for patients with Melanoma who carry the BRAF V600E mutation as well. Adverse effects from both Vemurafenib and Cobimetinib can include nausea, gastrointestinal issues and dizziness. The overall safety and tolerability of both of these medications has been documented in studies, both individually and as a combination. LGM Pharma provides Cobimetinib, CAS# 934660-93-2 and Vemurafenib APIs, CAS# 918504-65-1 for research and development purposes. Clients can be assured of quality API products and continuous support throughout the R&D process.
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.